COMPANY PROFILE

IceCure Medical

Explore full profile

Develops and markets minimally invasive cryoablation therapies for the treatment of breast cancer

Caesarea, IsraelFounded 2006Biotech & Life Sciences

Valuation $45M Market cap · 2023

Revenue $3.4M Latest reported FY

Total funding $10–50M Disclosed equity funding

About IceCure Medical

IceCure Medical is a pioneering company in the field of cryoablation technology, specializing in minimally invasive treatments for cancer tumors. The company primarily serves oncologists and interventional radiologists, offering solutions for breast, kidney, lung, liver, and bone cancer. Operating in the healthcare and medical device market, IceCure Medical's business model revolves around the development and commercialization of its proprietary ProSense™ system. This system uses liquid nitrogen-based technology to freeze and destroy cancerous tissues, providing a painless and effective alternative to traditional surgical methods. IceCure Medical generates revenue through the sale of its cryoablation systems and related consumables, as well as through partnerships and clinical trials. The company aims to establish its technology as the gold standard in cancer treatment, focusing on improving patient outcomes, reducing recovery times, and lowering healthcare costs. Keywords: cryoablation, cancer treatment, ProSense system, minimally invasive, oncology, interventional radiology, liquid nitrogen, healthcare, medical devices, tumor therapy.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Caesarea, Israel
Listing: IPO 2019
Employees: 78
Open positions: 1
Dealroom signal: 79.2/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Surgery, Ultrasound, Patient Care
Technology: Artificial Intelligence, Big Data, Deep Tech, Computer Vision
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT NON VC✓Other financing	Jun 2026	$5.5M	—	Undisclosed	↗
POST IPO EQUITY✓Other financing	Mar 2026	$4M	—	Undisclosed	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$3.4M	0%	−$16M	-488%	−$17M	-502.5%	$9.1M
2025	$3.4M	+2.7%	−$16M	-488%	−$17M	-502.5%	$9.1M
2024	$3.3M	+1.9%	−$16M	-501.1%	−$17M	-515.9%	$9.1M
2023	$3.2M	+4.7%	−$16M	-510.7%			$9.1M
2022	$3.1M	-25.4%	−$16M	-534.6%
2021	$4.1M	+7%	−$9.6M	-231.9%
2020	$3.9M	—	−$4.1M	-105.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

IceCure Medical website traffic

Latest recorded traffic for IceCure Medical is 12K monthly website visits, up 87.5% over the last three months. IceCure Medical's team grew 16.4% over the past year.

Latest monthly visits12K 3-month web change+87.5% 1-year team growth+16.4%

Monthly website visitsJun 2015–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Clinical Trial Assistant (CRA) – U.S. BasedAtlanta, Georgia, United States, Northern America, Americas · Other · Aug 27, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TMTrig MedicalInnovative non-invasive tracking and image-based guidance technology for labor monitoring and biopsy procedures	Nesher, Israel	Closed	4	$4.1M	$16M
GMGalil MedicalGalil Medical develops cryotherapy solutions that address patient conditions across multiple physician specialties	Saint Paul, United States	Acquired
IMiCellate MedicalDevelops products in the areas of cancer diagnosis, based on detection and analyses of circulating tumour cells (CTC), circulating tumour DNA (ctDNA) and germline DNA	Solna kommun, Sweden	Operational
BMBiop MedicalCompact optical device enabling real-time cervical examination to support detection of lesions and cancer and guide biopsy decisions	Netanya, Israel	Operational
P-P-CureP-Cure is a biotech company has developed a patient centric proton therapy solution with clinical benefits and financial advantages	Shilat, Israel	Operational
SMSadra MedicalFocused on developing minimal invasive alternatives to surgical valve replacement and improve patient care	Campbell, United States	Acquired
FEFEMSelectThe developer the FDA cleared and CE Marked system for suturing ligaments of the pelvic floor as an approach to minimally-invasive Pelvic Organ Prolapse (POP) procedures	Tel Aviv-Yafo, Israel	Operational
CMClearCut MedicalIntra-operative MRI for cancer detection in surgical specimens, for surgery, pathology and radiology	Rehovot, Israel	Operational